Clinical trials: Postmenopausal Disorder
Cardiovascular Disease, Diabetes
The FLAVO Trial: Dietary Flavonoids and Cardiovascular Disease Risk Reduction in Postmenopausal Women With Type 2 Diabetes
The purpose of this placebo controlled trial is to determine whether a year long intervention with flavonoids (found in cocoa and soy) is more effective in reducing the risk of cardiovascular disease in postmenopausal women with…
- Trial name
- FLAVO (NCT00677599)
- Testing
- Flavonoid enrichment (cocoa / soy compounds)
- Where
- United Kingdom
- Volunteers
- 152 people
- Sponsor
- University of East Anglia
Osteoporosis
Can Parathyroid Hormone Injections Reverse Glucocorticoid-induced Osteoporosis
Glucocorticoids are potent anti-inflammatory and immunosuppressive agents. However, prolonged use of these potent agents results in severe bone loss and osteoporotic fractures.
- Trial name
- NCT00004993
- Testing
- Parathyroid hormone (hPTH 1-34)
- Where
- United States
- Sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Atherosclerosis, Chlamydia Infections
Effects of Hormone Therapy on the Immune Systems of Postmenopausal Women With Chronic Infections
Hardening of the arteries (atherosclerosis) and heart disease are much more common in men than in women. However, as women grow older, especially after menopause the incidence of atherosclerosis and heart disease increases.
- Conditions
- Atherosclerosis, Chlamydia Infections, Cytomegalovirus Infections, Pneumonia, Bacterial
- Trial name
- NCT00001890
- Testing
- Estrogen therapy
- Where
- United States
- Volunteers
- 80 people
- Sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
Breast Cancer
Fulvestrant 500mg With Exemestane Endocrine Therapy for Postmenopausal Advanced Breast Cancer Patients
A Randomized, Open label, Parallel-group, Multi-center study. Eligible patients will be randomized in a 1:1 ratio to receive fulvestrant 500 mg or Exemestane 25mg.
- Trial name
- FRIEND (NCT02646735)
- Testing
- Fulvestrant 500 mg, Exemestane 25 mg
- Where
- China
- Volunteers
- 148 people
- Sponsor
- Chinese Academy of Medical Sciences
Breast Cancer
Efficacy and Safety of TAC and Exemestane as Neoadjuvant Chemotherapy in the Postmenopausal Women With Breast Cancer
Select the postmenopausal patients with breast cancer who is confirmed by core needle biopsy and at the clinical stage T2-4N0-2M0.Treat them with 4 cycles of TAC as neoadjuvant chemotherapy (Docetaxel was 75mg/m2, the EPI 60mg/m2…
- Trial name
- NCT01648608
- Testing
- Exemestane
- Where
- China
- Volunteers
- 600 people
- Sponsor
- Tianjin Medical University
Bone Density, Osteopenia
The Influence of Vibration on Bone Mineral Density in Women Who Have Weak Bones After Menopause
This study will examine whether whole-body vibration slows down bone loss in healthy postmenopausal women with osteopenia. Whole-body vibration is a promising novel therapy that involves standing on a platform which produces…
- Conditions
- Bone Density, Osteopenia, Osteoporosis, Post-Menopause
- Trial name
- NCT00420940
- Testing
- Juvent 1000 Dynamic Motion Therapy (DMT) Platform
- Where
- Canada
- Volunteers
- 202 people, healthy volunteers welcome
- Sponsor
- University Health Network, Toronto
Breast Neoplasms
Aromatase Inhibitor Host Factors Study
The purpose of this study is to examine how key patient factors, including body size affect how well letrozole suppresses circulating estrogen levels.
- Trial name
- NCT01669343
- Testing
- Letrozole
- Where
- 3 sites in Canada
- Volunteers
- 121 people
- Sponsor
- Samuel Lunenfeld Research Institute, Mount Sinai Hospital
Dyslipidemias, Hypertriglyceridemia
Effects of Phytoestrogen From Pueraria Mirifica in Improvement of Serum Lipid Parameters in Postmenopausal Women
The goal of this clinical trial is to learn about the effects of phytoestrogen from Pueraria Mirifica in improvement of serum lipid parameters.
- Conditions
- Dyslipidemias, Hypertriglyceridemia, Hypercholesterolemia, Hyper-LDL-cholesterolemia
- Trial name
- NCT06220266
- Testing
- Phytoestrogen, Diet control & life style modification
- Where
- Thailand
- Volunteers
- 10 people, healthy volunteers welcome
- Sponsor
- Dhurakij Pundit University
Breast Cancer
Faslodex Specific Clinical Experience Investigation
The purpose of this study is to confirm the safety profile such as the frequency of serious adverse events or any unexpected adverse events and overall efficacy of Faslodex for long term treatment in daily clinical practice.
- Trial name
- NCT01501266
- Where
- 43 sites in Japan
- Volunteers
- 660 people
- Sponsor
- AstraZeneca
Osteoporosis
CR9112792, a Follow-up of Study CR9108963
The purpose of this study is to determine whether bone mineral density has increased in a subgroup of postmenopausal osteoporotic women from study CR9108963, between 6 and 12 months following cessation of ronacaleret therapy.
- Trial name
- NCT00891553
- Testing
- DXA
- Where
- 3 sites in Denmark, Norway
- Volunteers
- 171 people
- Sponsor
- GlaxoSmithKline
Coronary Arteriosclerosis
Endothelial Progenitor Cells and Risk Factors for Coronary Artery Disease
This study will measure and compare the levels of endothelial progenitor cells (EPCs) in the blood of people with and without risk factors for atherosclerosis (hardening of the arteries) to see if there is a relationship between…
- Trial name
- NCT00013975
- Where
- United States
- Volunteers
- 120 people
- Sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
Cardiovascular Diseases, Heart Diseases
Postmenopausal Progestins, MI and Stroke
To evaluate the cardiovascular effects of postmenopausal hormone replacement therapy and the suspected beneficial effects on myocardial infarction and stroke.
- Conditions
- Cardiovascular Diseases, Heart Diseases, Coronary Disease, Cerebrovascular Accident
- Trial name
- NCT00005220
- Sponsor
- University of Washington
Postmenopausal Osteoporosis
Quality of Life in Postmenopausal Women With Osteoporosis
The researchers will evaluate the effectiveness of a complex intervention composed of multiple actions targeting primary care healthcare workers and postmenopausal women with osteoporosis by means of a quasi-experimental design…
- Trial name
- NCT03970902
- Testing
- Integrated Osteoporosis Care, Care As Usual
- Where
- Belgium
- Volunteers
- 239 people
- Sponsor
- University Ghent
Breast Cancer
Exemestane in Reducing Breast Density in Postmenopausal Women at Risk for Breast Cancer
RATIONALE: High estrogen levels may be associated with dense breast tissue and an increased risk of developing breast cancer. Exemestane may be effective in preventing the development of breast cancer by decreasing estrogen…
- Trial name
- NCT00066586
- Testing
- exemestane
- Where
- 12 sites in United States, Canada
- Volunteers
- 98 people
- Sponsor
- NCIC Clinical Trials Group
Postmenopausal Osteoporosis
Post-Marketing Drug Intensive Monitoring Surveillance of EDIROL in Patients With Postmenopausal Osteoporosis
This is a post-marketing drug intensive monitoring surveillance with an observational, non-interventional design. The objectives are to compare the incidence of hypercalcemia in patients with and without calcium intake (including…
- Trial name
- NCT05433207
- Testing
- Eldecalcitol soft capsules
- Where
- China
- Volunteers
- 1,000 people
- Sponsor
- Chugai Pharmaceutical
Low Bone Mineral Density
An Open-label, Single-arm Extension Study to Evaluate the Long-term Safety of Denosumab Administration in Postmenopausal Women With Low Bone Mineral Density
An Open-label, Single-arm Extension Study to Evaluate the Long-term Safety of Denosumab Administration in Postmenopausal Women with Low Bone Mineral Density
- Trial name
- NCT00325468
- Testing
- AMG 162
- Volunteers
- 200 people
- Sponsor
- Amgen
Breast Cancer
Liver Safety Under Upfront Arimidex vs Tamoxifen
The primary objective is to compare ARIMIDEX (anastrozole) 1 mg once daily with Tamoxifen 20 mg once daily as adjuvant treatment in terms of: incidence of fatty liver diseases.
- Trial name
- HEART (NCT00537771)
- Testing
- Anastrozole, Tamoxifen
- Where
- 16 sites in China
- Volunteers
- 384 people
- Sponsor
- AstraZeneca
Post Menopausal Osteoporosis
A Study of Ibandronate (Boniva) to Evaluate Bone Turnover Markers in Women With Treatment-Naive Postmenopausal Osteoporosis
This study will evaluate whether an early positive response to once-monthly oral ibandronate in treatment-naive participants with postmenopausal osteoporosis is predictive of efficacy later in treatment.
- Trial name
- NCT02598934
- Testing
- Ibandronate
- Where
- 53 sites in United States, Puerto Rico
- Volunteers
- 308 people
- Sponsor
- Hoffmann-La Roche
Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage IA Breast Cancer AJCC v8
Dietary and Exercise Interventions in Reducing Side Effects in Patients With Stage I-IIIa Breast Cancer Receiving Aromatase Inhibitors
This phase I/II trial studies how well dietary and exercise interventions work in reducing side effects in patients with stage I-IIIa breast cancer taking aromatase inhibitors.
- Conditions
- Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage IA Breast Cancer AJCC v8, Anatomic Stage IB Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8
- Trial name
- NCT03953157
- Testing
- Dietary Intervention, Exercise Intervention, Questionnaire Administration
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- Jonsson Comprehensive Cancer Center
Osteoporosis
Drug Holidays in the Treatment With Alendronate in Postmenopausal Women With Osteoporosis
The purpose of this study is to determine the duration of the treatment with alendronate in postmenopausal women with osteoporosis.
- Trial name
- NCT00936260
- Testing
- alendronate
- Where
- Spain
- Volunteers
- 228 people
- Sponsor
- Ciudad Universitaria, Spain